Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies.
Initial assessment of impact of adenovirus type 4 and type 7 vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012.
A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in US military recruits.
The fowl adenovirus type 4 was obtained from the Institute of Microbiology University of Agriculture Faisalabad Pakistan.
The treatments were given to all the groups after the challenge with fowl adenovirus type 4 having 104.
The final vaccine is composed of two enterically-coated tablets (one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7) designed to pass intact through the stomach and release the live virus in the intestine.
T'he formulation is similar to the previous vaccine so it is administered as two separate tablets: one tablet containing adenovirus type 4 and one tablet containing adenovirus type 7.
The first isolate of adenovirus type 4 was from a specimen collected on August 19, 1997, from an advanced training soldier whose illness met the case definition of ARD.
pyogenes, Group A, and adenovirus type 2 and adenovirus type 4, respectively, were identified.
The first isolate of adenovirus type 4 came from a patient who was hospitalized on May 22, 1997, approximately 7 weeks after administration of the adenovirus vaccines ended.
The percentage of cases from which adenovirus type 4 was isolated increased as the epidemic progressed.
The first reported outbreak of respiratory disease due to adenovirus type 4
in otherwise healthy young women.